JP2009539949A - 肺動脈性肺高血圧症の治療のためのバソペプチダーゼ阻害剤の使用 - Google Patents
肺動脈性肺高血圧症の治療のためのバソペプチダーゼ阻害剤の使用 Download PDFInfo
- Publication number
- JP2009539949A JP2009539949A JP2009514847A JP2009514847A JP2009539949A JP 2009539949 A JP2009539949 A JP 2009539949A JP 2009514847 A JP2009514847 A JP 2009514847A JP 2009514847 A JP2009514847 A JP 2009514847A JP 2009539949 A JP2009539949 A JP 2009539949A
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- inhibitor
- administration
- vasopeptidase
- pah
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
レンジアミン、クロロプロカイン、ジエタノールアミン、プロカイン、N-ベンジルフェネチルアミン、ジエチルアミン、ピペラジン、トリス(ヒドロキシメチル)-アミノメタン、水酸化テトラメチルアンモニウム、トリエチルアミン、ジベンジルアミン、エフェナミン、デヒドロアビエチルアミン、N-エチルピペリジン、ベンジルアミン、テトラメチルアンモニウム、テトラエチルアンモニウム、メチルアミン、ジメチルアミン、トリメチルアミン、エチルアミン、塩基性アミノ酸(例えばリシンおよびアルギニン)、およびジシクロへキシルアミンなどである。
毒性アルカロイドモノクロタリンの注射を受けたラットで認められているPAHモデルについて、ファシドトリルの長期効果を検討した(RosenbergおよびRabinovitch、Am. J. Physiol.、1988年、255、484頁)。毒素の単回注射(60mg/kg、皮下投与)後、肺動脈内皮が負傷し、動物は、重症肺動脈性肺高血圧症と右心室肥大とともに肺動脈平滑筋肥大を発症する。
ファシドトリルは、PAHモデルにおいて活性を示すと考えられるホスホジエステラーゼ5阻害剤のシルデナフィルと配合する(Schermulyら、Amer. J. Resp. Crit. Care Med.、2004年、169、39頁)。
Claims (11)
- PAHの治療および/または予防のための医薬の調製のための、単独の活性剤としての、またはホスホジエステラーゼ阻害剤と組み合わせてのバソペプチダーゼ阻害剤の使用。
- 前記バソペプチダーゼ阻害剤がファシドトリルである、請求項1に記載の使用。
- 前記医薬が経口経路による投与に適している、請求項1または2に記載の使用。
- 前記医薬が10から200mgのバソペプチダーゼ阻害剤の投与を可能にする、請求項1から3のいずれか一項に記載の使用。
- バソペプチダーゼ阻害剤およびホスホジエステラーゼ阻害剤と薬学的に許容可能なビヒクルの組み合わせ。
- 前記バソペプチダーゼ阻害剤がファシドトリルである、請求項4に記載の組み合わせ。
- 前記ホスホジエステラーゼ阻害剤がシルデナフィルである、請求項6に記載の組み合わせ。
- ファシドトリルおよびシルデナフィルを含む、請求項4から7のいずれか一項に記載の組み合わせ。
- 前記2つの活性成分を別個に同時投与し、または時間的に順次投与することを可能にする、請求項4から8のいずれか一項に記載の組み合わせ。
- 10から200mgのバソペプチダーゼ阻害剤および10から200mgのPDE-5阻害剤の投与を可能にする、請求項4から9のいずれか一項に記載の組み合わせ。
- PAHの治療および/または予防のための医薬の調製のための、請求項3から10のいずれか一項に記載の組み合わせの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0605250A FR2902009B1 (fr) | 2006-06-13 | 2006-06-13 | Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire |
FR0605250 | 2006-06-13 | ||
PCT/FR2007/000970 WO2007144501A2 (fr) | 2006-06-13 | 2007-06-12 | Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009539949A true JP2009539949A (ja) | 2009-11-19 |
JP5421099B2 JP5421099B2 (ja) | 2014-02-19 |
Family
ID=37603265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009514847A Expired - Fee Related JP5421099B2 (ja) | 2006-06-13 | 2007-06-12 | 肺動脈性肺高血圧症の治療のためのバソペプチダーゼ阻害剤の使用 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100234393A1 (ja) |
EP (1) | EP2026796B1 (ja) |
JP (1) | JP5421099B2 (ja) |
CA (1) | CA2655019C (ja) |
CY (1) | CY1118473T1 (ja) |
DK (1) | DK2026796T3 (ja) |
ES (1) | ES2611311T3 (ja) |
FR (1) | FR2902009B1 (ja) |
HR (1) | HRP20170123T1 (ja) |
HU (1) | HUE030538T2 (ja) |
LT (1) | LT2026796T (ja) |
PL (1) | PL2026796T3 (ja) |
PT (1) | PT2026796T (ja) |
RS (1) | RS55663B1 (ja) |
SI (1) | SI2026796T1 (ja) |
WO (1) | WO2007144501A2 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
JP2005529927A (ja) * | 2002-05-23 | 2005-10-06 | ファイザー インコーポレイテッド | 新規な組み合わせ |
WO2006026395A1 (en) * | 2004-08-26 | 2006-03-09 | Encysive Pharmaceuticals | Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof |
WO2006031931A2 (en) * | 2004-09-15 | 2006-03-23 | The President And Fellows Of Harvard College | Reducing er stress in the treatment of obesity and diabetes |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030040534A1 (en) * | 2001-04-16 | 2003-02-27 | Hughes David E. | Enantiomers of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide |
FR2837822B1 (fr) * | 2002-03-29 | 2004-06-04 | Bioprojet Soc Civ | Formes polymorphes du fasidotril, leurs procedes de preparation et compositions pharmaceutiques les contenant |
US20040077624A1 (en) * | 2002-05-23 | 2004-04-22 | Pfizer Inc. | Novel combination |
RU2006108864A (ru) * | 2003-08-22 | 2007-09-27 | Берингер Ингельхайм Фармасьютиклз, Инк. (Us) | Способы лечения хронического обструктивного заболевания легких (хозл) и легочной гипертензии |
BRPI0508880A (pt) * | 2004-03-17 | 2007-09-04 | Novartis Ag | uso de compostos orgánicos |
MXPA06012279A (es) * | 2004-04-23 | 2007-01-31 | Celgene Corp | Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar. |
WO2006126082A2 (en) * | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
-
2006
- 2006-06-13 FR FR0605250A patent/FR2902009B1/fr active Active
-
2007
- 2007-06-12 JP JP2009514847A patent/JP5421099B2/ja not_active Expired - Fee Related
- 2007-06-12 WO PCT/FR2007/000970 patent/WO2007144501A2/fr active Application Filing
- 2007-06-12 PL PL07788875T patent/PL2026796T3/pl unknown
- 2007-06-12 CA CA2655019A patent/CA2655019C/fr not_active Expired - Fee Related
- 2007-06-12 RS RS20170104A patent/RS55663B1/sr unknown
- 2007-06-12 US US12/303,981 patent/US20100234393A1/en not_active Abandoned
- 2007-06-12 PT PT77888758T patent/PT2026796T/pt unknown
- 2007-06-12 LT LTEP07788875.8T patent/LT2026796T/lt unknown
- 2007-06-12 SI SI200731887A patent/SI2026796T1/sl unknown
- 2007-06-12 DK DK07788875.8T patent/DK2026796T3/en active
- 2007-06-12 HU HUE07788875A patent/HUE030538T2/en unknown
- 2007-06-12 ES ES07788875.8T patent/ES2611311T3/es active Active
- 2007-06-12 EP EP07788875.8A patent/EP2026796B1/fr active Active
-
2017
- 2017-01-18 CY CY20171100067T patent/CY1118473T1/el unknown
- 2017-01-25 HR HRP20170123TT patent/HRP20170123T1/hr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005529927A (ja) * | 2002-05-23 | 2005-10-06 | ファイザー インコーポレイテッド | 新規な組み合わせ |
US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
WO2006026395A1 (en) * | 2004-08-26 | 2006-03-09 | Encysive Pharmaceuticals | Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof |
WO2006031931A2 (en) * | 2004-09-15 | 2006-03-23 | The President And Fellows Of Harvard College | Reducing er stress in the treatment of obesity and diabetes |
Non-Patent Citations (3)
Title |
---|
JPN5009008080; THE MERCK INDEX,13TH EDITION , 2001, P.THER-30, MERCK & CO.,INC. * |
JPN5009008082; BIN YAP LOK: CHEST V126 N4, 200410, P1330-1336 * |
JPN6013003125; 日本小児循環器学会雑誌 第21巻第6号, 2005, 653-659ページ * |
Also Published As
Publication number | Publication date |
---|---|
FR2902009A1 (fr) | 2007-12-14 |
EP2026796B1 (fr) | 2016-11-09 |
WO2007144501A3 (fr) | 2008-02-21 |
CA2655019A1 (fr) | 2007-12-21 |
HRP20170123T1 (hr) | 2017-03-24 |
JP5421099B2 (ja) | 2014-02-19 |
EP2026796A2 (fr) | 2009-02-25 |
DK2026796T3 (en) | 2017-02-06 |
CY1118473T1 (el) | 2017-07-12 |
LT2026796T (lt) | 2017-02-10 |
WO2007144501A2 (fr) | 2007-12-21 |
PT2026796T (pt) | 2017-01-17 |
ES2611311T3 (es) | 2017-05-08 |
US20100234393A1 (en) | 2010-09-16 |
FR2902009B1 (fr) | 2012-12-07 |
CA2655019C (fr) | 2014-11-25 |
PL2026796T3 (pl) | 2017-03-31 |
SI2026796T1 (sl) | 2017-02-28 |
RS55663B1 (sr) | 2017-06-30 |
HUE030538T2 (en) | 2017-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070197544A1 (en) | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension | |
US20210085695A1 (en) | Methods and compositions for the treatment of migraine headaches | |
ES2250283T3 (es) | Uso de cs-866 (olmesartan) en la preparacion de un medicamento para el tratamiento de la arteriosclerosis. | |
US11000527B2 (en) | Therapeutic methods and compositions | |
EP2129400A2 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
WO2007149283B1 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
CA3120920C (en) | Montelukast for the treatment of erosive hand osteoarthritis | |
JP2004505039A (ja) | Copdに付随する増悪の減少方法 | |
JP2002535367A5 (ja) | ||
JP5421099B2 (ja) | 肺動脈性肺高血圧症の治療のためのバソペプチダーゼ阻害剤の使用 | |
JP5925862B2 (ja) | セロトニン受容体介在状態を治療する方法及び組成物 | |
US20220168286A1 (en) | Treatment of raynaud's disease | |
JP2022546456A (ja) | 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン | |
WO1994002144A1 (en) | Use of 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone in the treatment of angina pectoris | |
WO2023009710A1 (en) | Treatment of hfpef in post-menopausal women with an sgc stimulator | |
KR20220128984A (ko) | sGC 자극제를 사용한 당뇨병성 신장병증의 치료 | |
Abarquez Jr et al. | Isradipine dose-confirmation study in Filipino patients with mild to moderate hypertension | |
MXPA06003273A (en) | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100514 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120710 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130430 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130927 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131022 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131121 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5421099 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |